

**CLEARBRIDGE HEALTH LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 201001436C)

---

**LEGAL PROCEEDINGS AGAINST FORMER DIRECTORS OF AN INDIRECT SUBSIDIARY IN  
INDONESIA – UPDATE**

---

*Unless otherwise defined herein or the context otherwise requires, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Company's announcement dated 10 June 2020 in relation to the Suit ("**Announcement**").*

Further to the Announcement, the Board of Clearbridge Health Limited (the "**Company**") wishes to update shareholders of the Company that the first hearing of the Suit has been scheduled for hearing before the Court on 7 July 2020.

The Company will make further announcements as and when there are further material updates and developments in respect of the Suit.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

**BY ORDER OF THE BOARD**

Yee Pinh Jeremy  
Chief Executive Officer and Executive Director

16 June 2020

---

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*